The treatment of recurrent vulvovaginal candidiasis includes an initial regimen of oral antimycotic drug to ensure clinical remission continued with maintenance therapy to prevent recurrent infection. This maintenance therapy should last at least 6 month. At the I. Department of Obstetrics and Gynecology of Semmelweis University we performed follow up of 24 nonpregnant patients with recurrent vulvovaginal candidiasis who had four or more previous episodes of proved infection during a 12-month period. After treating the acute fungal vaginitis with 1 x 150 mg (rarely 2 x 150 mg) oral fluconazole we started the maintenance therapy with topical boric acid. The efficacy of this topical maintenance therapy was measured with the occurrence of symptomatic recurrences during the period of prophylaxis and 6 months after. We also studied the side effects of oral fluconazole and topical boric acid treatment. 3 patients of the 24 (12,5%) were excluded from the study because interruption of the maintenance therapy. During the period of the maintenance therapy recurrent infection was not occurred among 18 patients of the remaining 21 (86%), although 3 patients (14%) experienced symptomatic fungal vaginitis. 7 patients fulfilled the 6 months after completing the period of topical boric acid prophylaxis. During this 6 months 2 patients of this 7 (29%) had acute episode, the remaining 5 (71%) did not experienced symptomatic infection. Side effects were not mentioned during the study. Topical boric acid seems to be an effective maintenance therapy in the prevention of relapses of recurrent vulvovaginal candidiasis.
|Translated title of the contribution||Treatment of chronic recurrent vulvovaginal candidiasis by oral fluconazole and prohylactic local boric acid|
|Number of pages||5|
|Journal||Magyar Noorvosok Lapja|
|Publication status||Published - Jan 1 2002|
ASJC Scopus subject areas
- Reproductive Medicine
- Obstetrics and Gynaecology